产品: | IFNAR1 抗体 |
货号: | AF6717 |
描述: | Rabbit polyclonal antibody to IFNAR1 |
应用: | IF/ICC |
反应: | Human |
分子量: | 55~70kD; 64kD(Calculated). |
蛋白号: | P17181 |
RRID: | AB_2847440 |
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF6717, RRID:AB_2847440.
展开/折叠
Alpha type antiviral protein; Antiviral protein, alpha-type; Antiviral protein, beta-type; AVP; Beta type antiviral protein; CRF2-1; Cytokine receptor class-II member 1; Cytokine receptor family 2 member 1; IFN alpha REC; IFN alpha receptor; IFN alpha/beta Receptor alpha; IFN beta receptor; IFN Interferon-beta receptor; IFN-alpha/beta receptor 1; IFN-R-1; IFNAR; Ifnar1; IFNBR; IFRC; INAR1_HUMAN; Interferon (alpha beta and omega) receptor 1; interferon alpha and beta receptor subunit 1; Interferon alpha/beta receptor 1; Interferon alpha/beta receptor alpha chain; Interferon beta receptor 1; interferon receptor 1; Interferon-alpha receptor; Type I interferon receptor 1;
抗原和靶标
A synthesized peptide derived from human IFNAR1.
IFN receptors are present in all tissues and even on the surface of most IFN-resistant cells. Isoform 1, isoform 2 and isoform 3 are expressed in the IFN-alpha sensitive myeloma cell line U266B1. Isoform 2 and isoform 3 are expressed in the IFN-alpha resistant myeloma cell line U266R. Isoform 1 is not expressed in IFN-alpha resistant myeloma cell line U266R.
- P17181 INAR1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERIENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDEYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSNEDESESKTSEELQQDFV
翻译修饰 - P17181 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
N58 | N-Glycosylation | Uniprot | |
T85 | Phosphorylation | Uniprot | |
K86 | Ubiquitination | Uniprot | |
K101 | Ubiquitination | Uniprot | |
N110 | N-Glycosylation | Uniprot | |
K125 | Ubiquitination | Uniprot | |
N172 | N-Glycosylation | Uniprot | |
K191 | Ubiquitination | Uniprot | |
K278 | Ubiquitination | Uniprot | |
N313 | N-Glycosylation | Uniprot | |
K397 | Ubiquitination | Uniprot | |
K414 | Ubiquitination | Uniprot | |
K417 | Ubiquitination | Uniprot | |
Y466 | Phosphorylation | P29597 (TYK2) | Uniprot |
Y481 | Phosphorylation | P29597 (TYK2) | Uniprot |
T494 | Phosphorylation | Uniprot | |
S495 | Phosphorylation | Uniprot | |
K501 | Ubiquitination | Uniprot | |
K525 | Ubiquitination | Uniprot | |
K526 | Ubiquitination | Uniprot | |
S532 | Phosphorylation | Q16539 (MAPK14) | Uniprot |
S535 | Phosphorylation | P48729 (CSNK1A1) , Q9BZL6 (PRKD2) | Uniprot |
Y538 | Phosphorylation | Uniprot | |
S539 | Phosphorylation | Uniprot |
研究背景
Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1. Functions in general as heterodimer with IFNAR2. Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves. Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity).
Ubiquitinated, leading to its internalization and degradation. Polyubiquitinated via 'Lys-48'-linked and 'Lys-63'-linked ubiquitin chains, leading to receptor internalization and lysosomal degradation. The 'Lys-63'-linked ubiquitin chains are cleaved off by the BRISC complex.
Phosphorylated on serine residues in response to interferon binding; this promotes interaction with FBXW11 and ubiquitination. Phosphorylated on tyrosine residues by TYK2 tyrosine kinase. Phosphorylated on tyrosine residues in response to interferon.
Palmitoylation at Cys-463 is required for the activation of STAT1 and STAT2.
Cell membrane>Single-pass type I membrane protein. Late endosome. Lysosome.
Note: Interferon binding triggers internalization of the receptor from the cell membrane into endosomes and then into lysosomes.
IFN receptors are present in all tissues and even on the surface of most IFN-resistant cells. Isoform 1, isoform 2 and isoform 3 are expressed in the IFN-alpha sensitive myeloma cell line U266B1. Isoform 2 and isoform 3 are expressed in the IFN-alpha resistant myeloma cell line U266R. Isoform 1 is not expressed in IFN-alpha resistant myeloma cell line U266R.
Heterodimer with IFNAR2. Interacts with STAT1 and STAT2; the interaction requires its phosphorylation at Tyr-466. Interacts with TYK2. Interacts (serine-phosphorylated form) with FBXW11, the substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex. Interacts with SHMT2; this promotes interaction with ABRAXAS2 and the BRISC complex.
Belongs to the type II cytokine receptor family.
研究领域
· Cellular Processes > Cell growth and death > Necroptosis. (View pathway)
· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)
· Human Diseases > Infectious diseases: Viral > Hepatitis C.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Infectious diseases: Viral > Measles.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.
· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Organismal Systems > Development > Osteoclast differentiation. (View pathway)
· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)
· Organismal Systems > Immune system > NOD-like receptor signaling pathway. (View pathway)
· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.